{
    "clinical_study": {
        "@rank": "85619", 
        "arm_group": [
            {
                "arm_group_label": "Capecitabine tablets", 
                "arm_group_type": "Experimental", 
                "description": "Single  oral Capecitabine tablets 2000mg qd"
            }, 
            {
                "arm_group_label": "XELODA", 
                "arm_group_type": "Active Comparator", 
                "description": "Single  oral XELODA 2000mg qd"
            }
        ], 
        "brief_summary": {
            "textblock": "1. purpose: To conduct the relative bioavalability study of Capecitabine tablets 500 mg\n           (Jiangsu Chia-Tai Tianqing Pharmacy Co. Ltd.) versus XELODA\u00ae 500 mg tablets\n           (Manufactured by Roche Pharma AG)\n\n        2. Experimental Design\uff1a Two-period crossover design\n\n        3. Test drug: Capecitabine tablets  Reference drug: XELODA\n\n        4. Sample size\uff1a24"
        }, 
        "brief_title": "A Bioequivalence Study of Capecitabine Tablets", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": "Metastatic Breast Cancer or Metastatic Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Colorectal Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must have histopathologically /cytologically confirmed breast cancer or\n             colorectal cancer\uff0cwithout chemotherapy or only adjuvant chemotherapy, and had\n             previously received one or two standard chemotherapy regimens for patients;\n\n          -  Age: 18-70 years, gender: both\uff0cBMI\u226517\uff0cEastern Cooperative Oncology Group (ECOG)\n             performance status\uff1a0-2\uff0cLife expectancy greater than 3 months;\n\n          -  Patients must have normal bone marrow function, liver and kidney function; adequate\n             organ function in the last 1 week, meeting the following: ANC\u22651.5\u00d7109/L\uff0cPLT\u226580\u00d7109/L,\n             Total bilirubin\u22641.5\u00d7the upper limit of normal, ALT,AST\u22642.5\u00d7the upper limit of normal,\n             creatinine\u22641.5\u00d7the institutional upper limit of normal.\n\n          -  Patients who has retreatment  could be enrolled at least 4 weeks after the last\n             chemotherapy and radiotherapy.\n\n          -  Patients must volunteer to participate and sign informed consent form.\n\n        Exclusion Criteria:\n\n          -  Suffering from heart, liver, kidney disease or severe acute and Organ invasion\n             disease;\n\n          -  Prior unanticipated severe reaction to fluoropyrimidine therapy, or known sensitivity\n             to 5-fluorouracil, or known DPD (Dihydropyrimidine Dehydrogenase) deficiency.\n\n          -  Pregnant or breast-feeding female\n\n          -  Only bone metastasis lesions, no other measurable lesions\n\n          -  Known brain metastasis or history of organ transplantation\n\n          -  Have long-term systemic steroid therapy\n\n          -  Serious diseases of vital organs; other malignancies which is not  cure\n\n          -  Use of chemotherapy in the last 4 weeks\n\n          -  History of drug/alcohol addiction or a positive hepatitis screen including hepatitis\n             B surface antigen, HCV or HAV (IgM) antibodies\n\n          -  Patient having abnormal serum calcium level at screening visit which as judged by\n             Investigator could lead to safety risk to the patient upon participation in the trial\n             or could interfere with the conduct of the trial.\n\n          -  Pre-existing motor or sensory neurotoxicity of a severity grade 2 by NCI CTCAE\n             criteria or known, existing uncontrolled coagulopathy.\n\n          -  Subjects are thought unsuitable for the study by investigators;\n\n          -  Inability to comply with protocol or study procedures in the opinion of the\n             investigator;"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01846650", 
            "org_study_id": "KPTB-1.1"
        }, 
        "intervention": [
            {
                "arm_group_label": "Capecitabine tablets", 
                "description": "Single oral Capecitabine tablets 2000mg qd", 
                "intervention_name": "Capecitabine tablets", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "XELODA", 
                "description": "Single oral XELODA 2000mg qd", 
                "intervention_name": "XELODA", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Capecitabine", 
                "Fluorouracil"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "September 28, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Xi an", 
                    "country": "China", 
                    "state": "Shanxi"
                }, 
                "name": "First Affiliated Hospital of Fourth Military Medical University"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Bioequivalence Study of Capecitabine Tablets in Patients of Locally Advanced or Metastatic Breast Cancer or Metastatic Colorectal Cancer", 
        "overall_official": {
            "affiliation": "First Affiliated Hospital of Fourth Military Medical University", 
            "last_name": "Wen Ai dong, doctor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Area Under Curve (AUC)", 
            "safety_issue": "No", 
            "time_frame": "predose, 0.33,0.67\uff0c1,1.5,2\uff0c2.5\uff0c3,4\uff0c5,6\uff0c8,hours post-dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01846650"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}